LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

MRK

119.68

+0.62%↑

LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

MRK

119.68

+0.62%↑

LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

MRK

119.68

+0.62%↑

LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

MRK

119.68

+0.62%↑

LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

MRK

119.68

+0.62%↑

Strona główna・Stock List・SCYNEXIS Inc

SCYNEXIS Inc

Closed

0.8 -3.61

Buy Sell

Overview

Share price change

24h

Current

Min

0.8

Max

0.82

Key metrics
By Trading Economics
Income	21M 12M
Sales	18M 19M
Profit margin	65.741
Employees	18
EBITDA	11M 11M

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+316.67% upside

Market Stats
By TradingEconomics
Market Cap	7.7M 39M
Previous open	4.41
Previous close	0.8

Technical Score

By Trading Central

Confidence

Weak Bullish Evidence

0.9307 / 0.9907 Support & Resistance

SCYNEXIS Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

27 mar 2026, 17:33 UTC

Major News Events

ECB Should Not Rush Its Response to Iran Conflict, Says Schnabel -- Update

27 mar 2026, 17:00 UTC

Major News Events

ECB Shouldn't Rush Its Response to Iran Conflict, Schnabel Says

27 mar 2026, 16:03 UTC

Major News Events

Fertilizer Maker Yara Warns Farmers Are Being Squeezed by Price Surge Amid War -- Commodities Roundup

27 mar 2026, 14:50 UTC

Major Market Movers

Cybersecurity Stocks Fall on Leak About New Claude Model's Cyber Capabilities

27 mar 2026, 14:37 UTC

Acquisitions, Mergers, Takeovers

Nestle's Water Business Stake Sale Could Value Unit at Around $5.76 billion, FT Says, Citing Sources

27 mar 2026, 14:29 UTC

Major News Events

EU Finance Ministers Tally Economic Hit of Iran War -- Update

27 mar 2026, 14:16 UTC

Major News Events

The Week in Oil: Mixed Signals Over U.S.-Iran Talks Keep Traders Wary

27 mar 2026, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

27 mar 2026, 19:16 UTC

Market Talk

Major News Events

Oil Futures Rise On Uncertainty Ahead of Weekend -- Market Talk

27 mar 2026, 19:07 UTC

Market Talk

U.S. Natural Gas Gains As April Contract Expires -- Market Talk

27 mar 2026, 19:04 UTC

Market Talk

Gold Rises But Can't Finish the Week Positive -- Market Talk

27 mar 2026, 19:03 UTC

Market Talk

Major News Events

Global Forex and Fixed Income Roundup: Market Talk

27 mar 2026, 19:02 UTC

Market Talk

Major News Events

Among Central Banks, Canada Has Room to Handle Oil Inflation -- Market Talk

27 mar 2026, 18:12 UTC

Market Talk

Foreign Fuels and Feedstocks to Get RINs Until 2028 -- Market Talk

27 mar 2026, 17:36 UTC

Major News Events

The Iran War and Oil Prices Bring Risk of Deeper Market Lows. There Are Echoes of 2008. -- Barrons.com

27 mar 2026, 17:34 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Delivery Hero Shares Bounce as Stake-Sale Report Whets Investor Appetites -- Market Talk

27 mar 2026, 17:29 UTC

Market Talk

U.S. Oil Rig Count Falls By 5 to 409 -- Market Talk

27 mar 2026, 16:38 UTC

Market Talk

Carnival's Outlook Assumes Oil Prices Will Come Down -- Market Talk

27 mar 2026, 16:32 UTC

Market Talk

Major News Events

Chinese Exposure to Higher Energy Costs Seen as Limited -- Market Talk

27 mar 2026, 16:20 UTC

Market Talk

Health Care Roundup: Market Talk

27 mar 2026, 15:43 UTC

Market Talk

Major News Events

Hormuz Closure Sends Tanker Rates to Record Highs -- Market Talk

27 mar 2026, 15:25 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

27 mar 2026, 15:25 UTC

Market Talk

Swiss Franc Dented by Rising European Yields, SNB Intervention Threats -- Market Talk

27 mar 2026, 15:00 UTC

Major News Events

Fed's Barkin: Inflation Progress 'May Be at Risk of Stalling'

27 mar 2026, 15:00 UTC

Major News Events

Fed's Barkin: Holding Rates Steady in March 'Felt Prudent'

27 mar 2026, 15:00 UTC

Major News Events

Fed's Barkin Says Iran War Raising Economic Uncertainty

27 mar 2026, 14:36 UTC

Market Talk

Major News Events

Rising Yields, Oil Prices Seen as Overreaction -- Market Talk

27 mar 2026, 14:26 UTC

Market Talk

Major News Events

Treasury Yields Mixed as Iran Peace Deal Remains Elusive -- Market Talk

27 mar 2026, 14:14 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

27 mar 2026, 14:14 UTC

Market Talk

Global Energy Roundup: Market Talk

Peer Comparison

Price change

SCYNEXIS Inc Forecast

Price Target

By TipRanks

316.67% upside

12 Months Forecast

Average 3.5 USD 316.67%

High 4 USD

Low 3 USD

Based on 2 Wall Street analysts offering 12 month price targets forSCYNEXIS Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

2 ratings

Buy

Hold

Sell

Based on 2 analysts giving stock ratings to SCYNEXIS Inc - Dist in the past 3 months.

Technical Score

By Trading Central

0.9307 / 0.9907Support & Resistance

Recent bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

There are no events.

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About SCYNEXIS Inc

SCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. It also develops SCY-247 to treat systemic fungal diseases. The company has licensing and collaboration agreements with GlaxoSmithKline Intellectual Property (No. 3) Limited, Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC for the development, manufacture, and commercialization of ibrexafungerp. SCYNEXIS, Inc. was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. The company was incorporated in 1999 and is headquartered in Jersey City, New Jersey.